Edition:
United States

Onconova Therapeutics Inc (ONTX.OQ)

ONTX.OQ on NASDAQ Stock Exchange Capital Market

1.40USD
3:59pm EST
Change (% chg)

$0.04 (+2.94%)
Prev Close
$1.36
Open
$1.36
Day's High
$1.45
Day's Low
$1.32
Volume
16,728
Avg. Vol
28,661
52-wk High
$3.88
52-wk Low
$1.32

Latest Key Developments (Source: Significant Developments)

Onconova Therapeutics files for mixed shelf offering of upto $84.5 mln
Monday, 20 Nov 2017 05:48pm EST 

Nov 20 (Reuters) - Onconova Therapeutics Inc ::Onconova Therapeutics Inc files for mixed shelf offering of upto $84.5 million- SEC filing‍​.  Full Article

Onconova Therapeutics prices public offering
Friday, 10 Nov 2017 07:00am EST 

Nov 10 (Reuters) - Onconova Therapeutics Inc :Onconova Therapeutics announces pricing of public offering of common stock.Agreed to sell approximately 920,000 shares of its common stock for gross proceeds of approximately $1.38 million​.Each share of common stock is being sold at a price of $1.50 per share​.  Full Article

Onconova Therapeutics reports Q3 revenue $100,000
Thursday, 9 Nov 2017 07:00am EST 

Nov 9 (Reuters) - Onconova Therapeutics Inc :Onconova Therapeutics, Inc. reports business highlights and third quarter 2017 financial results.Q3 revenue $100,000 versus $1.7 million.Q3 revenue view $152,000 -- Thomson Reuters I/B/E/S.Onconova Therapeutics Inc - Qtrly loss per share $0.71.  Full Article

Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics
Thursday, 21 Sep 2017 08:30am EDT 

Sept 21 (Reuters) - Cellectar Biosciences Inc :Cellectar Biosciences enters into strategic collaboration with Onconova Therapeutics to develop new phospholipid drug conjugates.Cellectar Biosciences Inc - financial terms of collaboration have not been disclosed.Cellectar Biosciences - ‍under terms of collaboration, Onconova will provide Cellectar with several compounds, including some from family of molecules that contains briciclib​.Cellectar Biosciences Inc - both companies will have option to advance development of any of newly conjugated PDC molecules.  Full Article

Onconova Therapeutics reports qtrly net loss per share of $0.29
Tuesday, 15 Aug 2017 07:00am EDT 

Aug 15 (Reuters) - Onconova Therapeutics Inc ::Onconova Therapeutics, Inc. reports recent business highlights and second quarter 2017 financial results.Qtrly net loss per share of common stock, basic and diluted $0.29.Q2 revenue $324,000 vs $2.2 million.  Full Article

Onconova Therapeutics Q1 loss per share $1.23
Monday, 15 May 2017 08:30am EDT 

May 15 (Reuters) - Onconova Therapeutics Inc :Onconova therapeutics, inc. Reports recent business highlights and first quarter 2017 financial results.Q1 revenue $200,000 versus $1.5 million.Onconova therapeutics inc - believes that its current cash and cash equivalents will be sufficient to fund its ongoing trials and operations to end of 2017.Onconova therapeutics inc - cash and cash equivalents as of march 31, 2017, totaled $15.4 million, compared to $21.4 million as of december 31, 2016.Q1 loss per share $1.23.Q1 earnings per share view $-1.01, revenue view $160000.00 -- Thomson Reuters I/B/E/S.  Full Article

Sabby Management LLC reports 7.61 percent passive stake in Onconova Therapeutics
Monday, 1 May 2017 12:28pm EDT 

May 1 (Reuters) - Onconova Therapeutics Inc :Sabby Management LLC reports 7.61 percent passive stake in Onconova Therapeutics Inc as of April 21 - sec filing.  Full Article

ONCONOVA THERAPEUTICS PRICES PUBLIC OFFERING OF COMMON STOCK AT $2.10/SHARE
Friday, 21 Apr 2017 09:41am EDT 

April 21 (Reuters) - Onconova Therapeutics Inc :ONCONOVA THERAPEUTICS ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK.SAYS PUBLIC OFFERING OF 2.48 MILLION COMMON SHARES PRICED AT $2.10PER SHARE.  Full Article

Onconova Therapeutics reports proposed public offering of common stock
Thursday, 20 Apr 2017 07:47pm EDT 

April 20 (Reuters) - Onconova Therapeutics Inc ::Onconova Therapeutics announces proposed public offering of common stock.Onconova Therapeutics Inc - intends to use net proceeds from offering to support development of rigosertib for treatment in higher risk mds.  Full Article

Onconova Therapeutics says entered market issuance sales agreement with FBR Capital
Thursday, 20 Apr 2017 05:55pm EDT 

April 20 (Reuters) - Onconova Therapeutics Inc ::Onconova Therapeutics- on dec. 5, 2016, co entered into at market issuance sales agreement with FBR capital to create an at--market equity program.Onconova Therapeutics Inc - effective april 19, 2017, company terminated sales agreement and related atm program - sec filing.Onconova Therapeutics Inc - has decided to terminate sales agreement because it does not intend to utilize sales agreement to raise additional capital.Onconova Therapeutics Inc - company will not incur any termination penalties as a result of its termination of sales agreement.  Full Article

BRIEF-Onconova Therapeutics files for mixed shelf offering of upto $84.5 mln

* Onconova Therapeutics Inc files for mixed shelf offering of upto $84.5 million- SEC filing‍​ Source text: (http://bit.ly/2AiGwl1) Further company coverage: